Prostate-Specific Antigen

• 

  Subject Areas on Research

  • A comparison of radical retropubic with perineal prostatectomy for localized prostate cancer within the Uniformed Services Urology Research Group. 
  • A contemporary prognostic nomogram for men with hormone-refractory metastatic prostate cancer: a TAX327 study analysis. 
  • A double-blind, randomized, neoadjuvant study of the tissue effects of POMx pills in men with prostate cancer before radical prostatectomy. 
  • A framework for the identification of men at increased risk for prostate cancer. 
  • A framework to evaluate the cost-effectiveness of the NADiA ProsVue slope to guide adjuvant radiotherapy among men with high-risk characteristics following prostatectomy for prostate cancer. 
  • A phase 2 multimodality trial of docetaxel/prednisone with sunitinib followed by salvage radiation therapy in men with PSA recurrent prostate cancer after radical prostatectomy. 
  • A phase II study of docetaxel (Taxotere), estramustine, and low-dose hydrocortisone in men with hormone-refractory prostate cancer: preliminary results of cancer and leukemia group B Trial 9780. 
  • A phase II study of estramustine, docetaxel, and carboplatin with granulocyte-colony-stimulating factor support in patients with hormone-refractory prostate carcinoma: Cancer and Leukemia Group B 99813. 
  • A phase II study of estramustine, docetaxel, and exisulind in patients with hormone- refractory prostate cancer: results of cancer and leukemia group B trial 90004. 
  • A phase II study of weekly paclitaxel/estramustine/carboplatin in hormone-refractory prostate cancer. 
  • A phase II trial of temsirolimus in men with castration-resistant metastatic prostate cancer. 
  • A prognostic score for hormone-refractory prostate cancer: analysis of two cancer and leukemia group B studies. 
  • A randomized trial of diet in men with early stage prostate cancer on active surveillance: rationale and design of the Men's Eating and Living (MEAL) Study (CALGB 70807 [Alliance]). 
  • A simple model predicts freedom from biochemical recurrence after low-dose rate prostate brachytherapy alone. 
  • A structured literature review to determine the use of the American Society for Therapeutic Radiology and Oncology consensus definition of biochemical failure. 
  • ACR Appropriateness Criteria® Post-treatment Follow-up Prostate Cancer. 
  • ACR Appropriateness Criteria® Prostate Cancer-Pretreatment Detection, Surveillance, and Staging. 
  • Abdominal obesity as risk factor for prostate cancer diagnosis and high grade disease: a prospective multicenter Italian cohort study. 
  • Abiraterone acetate for patients with metastatic castration-resistant prostate cancer progressing after chemotherapy: final analysis of a multicentre, open-label, early-access protocol trial. 
  • Accuracy of predicting long-term prostate specific antigen outcome based on early prostate specific antigen recurrence results after radical prostatectomy. 
  • Active surveillance as a treatment option for prostate cancer. 
  • Active surveillance for African-American men with prostate cancer: of course! Pro. 
  • Active surveillance for early-stage prostate cancer: review of the current literature. 
  • Active surveillance for prostate cancer: can we modernize contemporary protocols to improve patient selection and outcomes in the focal therapy era? 
  • Activity of the herbal combination, PC-SPES, in the treatment of patients with androgen-independent prostate cancer. 
  • Acute urinary toxicity following transperineal prostate brachytherapy using a modified Quimby loading method. 
  • Addition of estramustine to chemotherapy and survival of patients with castration-refractory prostate cancer: a meta-analysis of individual patient data. 
  • Additional analysis of the secondary end point of biochemical recurrence rate in a phase 3 trial (CS21) comparing degarelix 80 mg versus leuprolide in prostate cancer patients segmented by baseline characteristics. 
  • Adenocarcinoma of the prostate: epidemiological trends, screening, diagnosis, and surgical management of localized disease. 
  • Adjuvant and salvage radiation therapy after prostatectomy: American Society for Radiation Oncology/American Urological Association guidelines. 
  • Adjuvant radiotherapy for pathologic stage T3/4 adenocarcinoma of the prostate: ten-year update. 
  • Adjuvant versus salvage radiation therapy for prostate cancer and the risk of death. 
  • Adrenal androgen levels as predictors of outcome in prostate cancer patients treated with ketoconazole plus antiandrogen withdrawal: results from a cancer and leukemia group B study. 
  • Adverse pathology and undetectable ultrasensitive prostate-specific antigen after radical prostatectomy: is adjuvant radiation warranted? 
  • African American Men With Low-Risk Prostate Cancer Are Candidates for Active Surveillance: The Will-Rogers Effect? 
  • After radical retropubic prostatectomy 'insignificant' prostate cancer has a risk of progression similar to low-risk 'significant' cancer. 
  • Age adjusted prostate specific antigen and prostate specific antigen velocity cut points in prostate cancer screening. 
  • Age-specific distribution of serum prostate-specific antigen in a community-based study of African-American men. 
  • Age-specific reference ranges for serum prostate-specific antigen in black men. 
  • Alcohol intake increases high-grade prostate cancer risk among men taking dutasteride in the REDUCE trial. 
  • American Society of Clinical Oncology 2013 top five list in oncology. 
  • An Observational Study of Concomitant Use of Emerging Therapies and Denosumab or Zoledronic Acid in Prostate Cancer. 
  • An examination of the dynamic changes in prostate-specific antigen occurring in a population-based cohort of men over time. 
  • Androgen receptor down-regulation in prostate cancer with phosphorodiamidate morpholino antisense oligomers. 
  • Antiandrogen withdrawal alone or in combination with ketoconazole in androgen-independent prostate cancer patients: a phase III trial (CALGB 9583). 
  • Apical soft tissue biopsies predict biochemical failure in radical perineal prostatectomy patients with apical cancer involvement. 
  • Are repeat prostate biopsies safe? A cohort analysis from the SEARCH database. 
  • Aspirin, NSAIDs, and risk of prostate cancer: results from the REDUCE study. 
  • Assessing follow-up care after prostate-specific antigen elevation in American Indian / Alaska Native Men: a partnership approach. 
  • Association Between Choice of Radical Prostatectomy, External Beam Radiotherapy, Brachytherapy, or Active Surveillance and Patient-Reported Quality of Life Among Men With Localized Prostate Cancer. 
  • Association Between RECIST Changes and Survival in Patients with Metastatic Castration-resistant Prostate Cancer Receiving Docetaxel. 
  • Association between percentage of tumor involvement and Gleason score upgrading in low-risk prostate cancer. 
  • Association between preoperative erectile dysfunction and prostate cancer features--an analysis from the Duke Prostate Center Database. 
  • Association between systemic inflammatory markers and serum prostate-specific antigen in men without prostatic disease - the 2001-2008 National Health and Nutrition Examination Survey. 
  • Association of cigarette smoking with interval to biochemical recurrence after radical prostatectomy: results from the SEARCH database. 
  • Association of prostate-specific antigen doubling time and cancer in men undergoing repeat prostate biopsy. 
  • Associations Between Prostate Volume and Oncologic Outcomes in Men Undergoing Focal Cryoablation of the Prostate. 
  • Autoantibodies against the cell surface-associated chaperone GRP78 stimulate tumor growth via tissue factor. 
  • Autologous dendritic cells transfected with prostate-specific antigen RNA stimulate CTL responses against metastatic prostate tumors. 
  • Azacitidine favorably modulates PSA kinetics correlating with plasma DNA LINE-1 hypomethylation in men with chemonaïve castration-resistant prostate cancer. 
  • Balancing Risks in Prostate-specific Antigen Recurrence: The Fox Versus the Hedgehog. 
  • Baseline PSA as a predictor of prostate cancer-specific mortality over the past 2 decades: Duke University experience. 
  • Baseline prostate inflammation is associated with a reduced risk of prostate cancer in men undergoing repeat prostate biopsy: results from the REDUCE study. 
  • Baseline prostate-specific antigen testing at a young age. 
  • Benign prostatic hyperplasia. New concepts in the 1990s. 
  • Best screening tests for prostate cancer. 
  • Biochemical failure after radical prostatectomy in men with pathologic organ-confined disease: pT2a versus pT2b. 
  • Biochemical recurrence after definitive prostate cancer therapy. Part I: defining and localizing biochemical recurrence of prostate cancer. 
  • Biochemical recurrence after definitive prostate cancer therapy. Part II: treatment strategies for biochemical recurrence of prostate cancer. 
  • Biochemical recurrence of prostate cancer. 
  • Biologically effective dose (BED) correlation with biochemical control after low-dose rate prostate brachytherapy for clinically low-risk prostate cancer. 
  • Biomarkers in the management and treatment of men with metastatic castration-resistant prostate cancer. 
  • Biopsy accuracy in identifying unilateral prostate cancer depends on prostate weight. 
  • Blinded evaluation of reverse transcriptase-polymerase chain reaction prostate-specific antigen peripheral blood assay for molecular staging of prostate cancer. 
  • Body composition and serum prostate-specific antigen: review and findings from Flint Men's Health Study. 
  • Body mass index and prostate specific antigen as predictors of adverse pathology and biochemical recurrence after prostatectomy. 
  • Body mass index, prostate-specific antigen, and digital rectal examination findings among participants in a prostate cancer screening clinic. 
  • CD34 immunohistochemical assessment of angiogenesis as a prognostic marker for prostate cancer recurrence after radical prostatectomy. 
  • Cabozantinib in chemotherapy-pretreated metastatic castration-resistant prostate cancer: results of a phase II nonrandomized expansion study. 
  • Cadmium-induced neoplastic transformation of human prostate epithelial cells. 
  • Can Radiologic Staging With Multiparametric MRI Enhance the Accuracy of the Partin Tables in Predicting Organ-Confined Prostate Cancer? 
  • Can prostate-specific antigen and prostate-specific antigen velocity be used for prostate cancer screening in men older than 70 years? 
  • Cancer control after low-dose-rate prostate brachytherapy performed by a multidisciplinary team with no previous prostate brachytherapy experience. 
  • Cancer-specific mortality after surgery or radiation for patients with clinically localized prostate cancer managed during the prostate-specific antigen era. 
  • Capromab Pendetide imaging of prostate cancer. 
  • Carcinoma extent in prostate needle biopsy tissue in the prediction of whole gland tumor volume in a screening population. 
  • Cell-specific aptamers for targeted therapies. 
  • Challenges and recommendations for early identification of metastatic disease in prostate cancer. 
  • Changes in alkaline phosphatase levels in patients with prostate cancer receiving degarelix or leuprolide: results from a 12-month, comparative, phase III study. 
  • Changing face and different countenances of prostate cancer: racial and geographic differences in prostate-specific antigen (PSA), stage, and grade trends in the PSA era. 
  • Characteristics of baseline PSA and PSA velocity in young men without prostate cancer: Racial differences. 
  • Characterization and predictors of prostate specific antigen progression rates after radical retropubic prostatectomy. 
  • Cigarette smoking is associated with an increased risk of biochemical disease recurrence, metastasis, castration-resistant prostate cancer, and mortality after radical prostatectomy: results from the SEARCH database. 
  • Cilengitide (EMD 121974, NSC 707544) in asymptomatic metastatic castration resistant prostate cancer patients: a randomized phase II trial by the prostate cancer clinical trials consortium. 
  • Circulating Tumor Cells in Biochemical Recurrence of Prostate Cancer. 
  • Clinical Outcomes of Chemotherapy Naïve Men with Metastatic Castration Resistant Prostate Cancer and Low Baseline Prostate Specific Antigen Treated with Enzalutamide vs Placebo. 
  • Clinical activity of abiraterone acetate in patients with metastatic castration-resistant prostate cancer progressing after enzalutamide. 
  • Clinical and biochemical evidence of control of prostate cancer at 5 years after external beam radiation. 
  • Clinical and pathologic outcome after radical prostatectomy for prostate cancer patients with a preoperative Gleason sum of 8 to 10. 
  • Clinical characteristics of African-American men with hereditary prostate cancer: the AAHPC Study. 
  • Clinical endpoints for drug development in prostate cancer. 
  • Clinical outcomes and survival surrogacy studies of prostate-specific antigen declines following enzalutamide in men with metastatic castration-resistant prostate cancer previously treated with docetaxel. 
  • Clinical phenotypes associated with circulating tumor cell enumeration in metastatic castration-resistant prostate cancer. 
  • Clinical utility of indium 111-capromab pendetide immunoscintigraphy in the detection of early, recurrent prostate carcinoma after radical prostatectomy. 
  • Clinically relevant changes in family history of cancer over time. 
  • Combination external beam radiation and brachytherapy boost with androgen suppression for treatment of intermediate-risk prostate cancer: an initial report of CALGB 99809. 
  • Combined external beam irradiation and external regional hyperthermia for locally advanced adenocarcinoma of the prostate. 
  • Combined low-dose flutamide plus finasteride vs low-dose flutamide monotherapy for recurrent prostate cancer: a comparative analysis of two phase II trials with a long-term follow-up. 
  • Combining prostate specific antigen with cancer and gland volume to predict more reliably pathological stage: the influence of prostate specific antigen cancer density. 
  • Comments on: High-dose-rate interstitial brachytherapy as monotherapy in one fraction of 20.5 Gy for the treatment of localize prostate cancer: toxicity and 6-years biochemical results. 
  • Common variation in the BRCA1 gene and prostate cancer risk. 
  • Comparative analysis of prostate-specific antigen free survival outcomes for patients with low, intermediate and high risk prostate cancer treatment by radical therapy. Results from the Prostate Cancer Results Study Group. 
  • Comparison of DRE and PSA in the Detection of Prostate Cancer. 
  • Comparison of Outcomes Between Preoperatively Potent Men Treated with Focal Versus Whole Gland Cryotherapy in a Matched Population. 
  • Comparison of fresh frozen serum to proficiency testing material in College of American Pathologists surveys: alpha-fetoprotein, carcinoembryonic antigen, human chorionic gonadotropin, and prostate-specific antigen. 
  • Comparison of preoperative prostate specific antigen density and prostate specific antigen for predicting recurrence after radical prostatectomy: results from the search data base. 
  • Comparison of prostate-specific antigen recurrence-free survival in a contemporary cohort of patients undergoing either radical retropubic or robot-assisted laparoscopic radical prostatectomy. 
  • Comparison of radical prostatectomy and iodine 125 interstitial radiotherapy for the treatment of clinically localized prostate cancer: a 7-year biochemical (PSA) progression analysis. 
  • Comparison of serum prostate specific membrane antigen, prostate specific antigen, and free prostate specific antigen levels in radical prostatectomy patients. 
  • Complete Biochemical Response (Prostate Specific Antigen) to Sipuleucel-T in Metastatic Castrate-Resistant Prostate Cancer: A Case Report With Docetaxel Chemotherapy Administered Just Before Sipuleucel-T. 
  • Conformal technique dose escalation for prostate cancer: biochemical evidence of improved cancer control with higher doses in patients with pretreatment prostate-specific antigen > or = 10 NG/ML. 
  • Conformal treatment of prostate cancer with improved targeting: superior prostate-specific antigen response compared to standard treatment. 
  • Contemporary role of systematic prostate biopsies: indications, techniques, and implications for patient care. 
  • Correlation of prostate-specific antigen nadir and biochemical failure after high-intensity focused ultrasound of localized prostate cancer based on the Stuttgart failure criteria - analysis from the @-Registry. 
  • Cost implications of PSA screening differ by age. 
  • Dasatinib combined with docetaxel for castration-resistant prostate cancer: results from a phase 1-2 study. 
  • Death in patients with recurrent prostate cancer after radical prostatectomy: prostate-specific antigen doubling time subgroups and their associated contributions to all-cause mortality. 
  • Decreasing age at prostate cancer diagnosis over successive generations in prostate cancer families. 
  • Defining and treating high-risk prostate cancer: can we do better? 
  • Defining low-value PSA testing in a large retrospective cohort: Finding common ground between discordant guidelines. 
  • Defining the ideal cutpoint for determining PSA recurrence after radical prostatectomy. Prostate-specific antigen. 
  • Definition and preoperative predictors of persistently elevated prostate-specific antigen after radical prostatectomy: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database. 
  • Delayed prostate-specific antigen recurrence after radical prostatectomy: how to identify and what are their clinical outcomes? 
  • Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. 
  • Detectable prostate-specific antigen Nadir during androgen-deprivation therapy predicts adverse prostate cancer-specific outcomes: results from the SEARCH database. 
  • Detection of circulating prostate specific antigen expressing prostatic cells in the bone marrow of radical prostatectomy patients by sensitive reverse transcriptase polymerase chain reaction. 
  • Detection of previously unidentified metastatic disease as a leading cause of screening failure in a phase III trial of zibotentan versus placebo in patients with nonmetastatic, castration resistant prostate cancer. 
  • Determining optimal prostate-specific antigen thresholds to identify an increased 4-year risk of prostate cancer development: an analysis within the Veterans Affairs Health Care System. 
  • Development and clinical validation of a real-time PCR assay for PITX2 DNA methylation to predict prostate-specific antigen recurrence in prostate cancer patients following radical prostatectomy. 
  • Development of gene therapy for prostate cancer using a novel promoter of prostate-specific antigen. 
  • Diabetes and outcomes after radical prostatectomy: are results affected by obesity and race? Results from the shared equal-access regional cancer hospital database. 
  • Diagnostic potential of prostate-specific antigen expressing epithelial cells in blood of prostate cancer patients. 
  • Dissecting the dynamics of serum prostate-specific antigen. 
  • Do nomograms designed to predict biochemical recurrence (BCR) do a better job of predicting more clinically relevant prostate cancer outcomes than BCR? A report from the SEARCH database group. 
  • Do nomograms predict aggressive recurrence after radical prostatectomy more accurately than biochemical recurrence alone? 
  • Do racial differences in prostate size explain higher serum prostate-specific antigen concentrations among black men? 
  • Do the current subclassifications of stage T3 adenocarcinoma of the prostate have clinical relevance? 
  • Do younger men have better biochemical outcomes after radical prostatectomy? 
  • Docetaxel and dasatinib or placebo in men with metastatic castration-resistant prostate cancer (READY): a randomised, double-blind phase 3 trial. 
  • Docetaxel for advanced prostate cancer: how early to start? 
  • Does Any Racial Disparity Exist in Oncologic Outcomes After Primary Cryotherapy for Prostate Cancer? A Matched-pair Comparative Analysis of the Cryo On-Line Data Registry. 
  • Does Obesity Modify the Ability of Prebiopsy Prostate Specific Antigen to Detect Prostate Cancer on Repeat Biopsy? Results from the REDUCE Study. 
  • Does PSADT after radical prostatectomy correlate with overall survival?--a report from the SEARCH database group. 
  • Does a delay in initiating definitive therapy affect biochemical recurrence rates in men with clinically localized prostate cancer? 
  • Does early prostate-specific antigen doubling time (ePSADT) after radical prostatectomy, calculated using PSA values from the first detectable until the first recurrence value, correlate with standard PSADT? A report from the Shared Equal Access Regional Cancer Hospital Database Group. 
  • Does larger tumor volume explain the higher prostate specific antigen levels in black men with prostate cancer--Results from the SEARCH database. 
  • Does prior benign prostate biopsy predict outcome for patients treated with radical perineal prostatectomy? 
  • Does salvage radiation therapy change the biology of recurrent prostate cancer based on PSA doubling times? Results from the SEARCH database. 
  • Dose escalation of oral vinorelbine in combination with estramustine in hormone-refractory adenocarcinoma of the prostate. 
  • Dosimetric quantifiers for low-dose-rate prostate brachytherapy: is V(100) superior to D(90)? 
  • Dosimetry and cancer control after low-dose-rate prostate brachytherapy. 
  • Drug development in prostate cancer: time to embrace RECIST? 
  • Dynamic prediction of metastases after radical prostatectomy for prostate cancer. 
  • Early detection of prostate cancer: AUA Guideline. 
  • Early prostate cancer: prevention, treatment modalities, and quality of life issues. 
  • Early prostate cancer: the national results of radiation treatment from the Patterns of Care and Radiation Therapy Oncology Group studies with prospects for improvement with conformal radiation and adjuvant androgen deprivation. 
  • Early results of prostate cancer radiation therapy: an analysis with emphasis on research strategies to improve treatment delivery and outcomes. 
  • Early versus delayed hormonal therapy for prostate specific antigen only recurrence of prostate cancer after radical prostatectomy. 
  • Editorial Comment. 
  • Editorial Comment. 
  • Editorial comment on: Development of a new method for monitoring prostate-specific antigen changes in men with localised prostate cancer: a comparison of observational cohorts. 
  • Editorial comment. 
  • Editorial comment. 
  • Editorial comment. Which patients with undetectable PSA levels 5 years after radical prostatectomy are still at risk of recurrence?--Implications for a risk-adapted follow-up strategy. 
  • Effect of age and pathologic Gleason score on PSA recurrence: analysis of 2911 patients undergoing radical prostatectomy. 
  • Effect of age on biochemical disease-free outcome in patients with T1-T3 prostate cancer treated with definitive radiotherapy in an equal-access health care system: a radiation oncology report of the Department of Defense Center for Prostate Disease Research. 
  • Effect of flexible cystoscopy on serum prostate-specific antigen values. 
  • Effect of isocaloric low-fat diet on prostate cancer xenograft progression to androgen independence. 
  • Effect of practice integration between urologists and radiation oncologists on prostate cancer treatment patterns. 
  • Effect of race and socioeconomic status on surgical margins and biochemical outcomes in an equal-access health care setting: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database. 
  • Effect of race on biochemical disease-free outcome in patients with prostate cancer treated with definitive radiation therapy in an equal-access health care system: radiation oncology report of the Department of Defense Center for Prostate Disease Research. 
  • Efficacy of docetaxel-based chemotherapy following ketoconazole in metastatic castration-resistant prostate cancer: implications for prior therapy in clinical trials. 
  • Efficacy of peripheral androgen blockade in prostate cancer patients with biochemical failure after definitive local therapy: results of Cancer and Leukemia Group B (CALGB) 9782. 
  • Elastomeric negative acoustic contrast particles for affinity capture assays. 
  • Elective irradiation of pelvic lymph nodes during postprostatectomy salvage radiotherapy. 
  • Eligibility and outcomes reporting guidelines for clinical trials for patients in the state of a rising prostate-specific antigen: recommendations from the Prostate-Specific Antigen Working Group. 
  • Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group. 
  • Endocrine effects, efficacy and tolerability of a 10.8-mg depot formulation of goserelin acetate administered every 13 weeks to patients with advanced prostate cancer. 
  • Entropy and information content of laboratory test results. 
  • Enzalutamide Versus Bicalutamide in Castration-Resistant Prostate Cancer: The STRIVE Trial. 
  • Epidemiology and screening for prostate cancer. 
  • Equivalent uniform dose, D(90), and V(100) correlation with biochemical control after low-dose-rate prostate brachytherapy for clinically low-risk prostate cancer. 
  • Estimated blood loss as a predictor of PSA recurrence after radical prostatectomy: results from the SEARCH database. 
  • Evaluating the PCPT risk calculator in ten international biopsy cohorts: results from the Prostate Biopsy Collaborative Group. 
  • Evaluating the Prostate Cancer Prevention Trial High Grade Prostate Cancer Risk Calculator in 10 international biopsy cohorts: results from the Prostate Biopsy Collaborative Group. 
  • Evaluating the value of number of cycles of docetaxel and prednisone in men with metastatic castration-resistant prostate cancer. 
  • Evaluation and Active Treatment versus Active Surveillance of Localized Prostate Cancer in Renal Transplant Patients in the Era of Low and Very Low Risk Prostate Cancer. 
  • Evaluation of a novel precision template-guided biopsy system for detecting prostate cancer. 
  • Evaluation of an epithelial plasticity biomarker panel in men with localized prostate cancer. 
  • Evidence of increased failure in the treatment of prostate carcinoma patients who have perineural invasion treated with three-dimensional conformal radiation therapy. 
  • Exploring the Clinical Benefit of Docetaxel or Enzalutamide After Disease Progression During Abiraterone Acetate and Prednisone Treatment in Men With Metastatic Castration-Resistant Prostate Cancer. 
  • Exposure to Agent Orange is a significant predictor of prostate-specific antigen (PSA)-based recurrence and a rapid PSA doubling time after radical prostatectomy. 
  • Expression of androgen and estrogen related proteins in normal weight and obese prostate cancer patients. 
  • External validation of the SEARCH model for predicting aggressive recurrence after radical prostatectomy: results from the Duke Prostate Center Database. 
  • FSH suppression and tumour control in patients with prostate cancer during androgen deprivation with a GnRH agonist or antagonist. 
  • Factors associated with blood loss during radical prostatectomy for localized prostate cancer in the prostate-specific antigen (PSA)-era: an overview of the Department of Defense (DOD) Center for Prostate Disease Research (CPDR) national database. 
  • Factors predicting prostatic biopsy Gleason sum under grading. 
  • Family history of prostate cancer and relapse after definitive external beam radiation therapy. 
  • Financial comparative analysis of minimally invasive surgery to open surgery for localized prostate cancer: a single-institution experience. 
  • Finasteride and bicalutamide as primary hormonal therapy in patients with advanced adenocarcinoma of the prostate. 
  • Finasteride in association with either flutamide or goserelin as combination hormonal therapy in patients with stage M1 carcinoma of the prostate gland. International Prostate Health Council (IPHC) Trial Study Group. 
  • Five-Year Biochemical Progression-Free Survival Following Salvage Whole-Gland Prostate Cryoablation: Defining Success with Nadir Prostate-Specific Antigen. 
  • Five-year downstream outcomes following prostate-specific antigen screening in older men. 
  • Focal cryotherapy for prostate cancer. 
  • Focal therapy of prostate cancer: evidence-based analysis for modern selection criteria. 
  • Focal therapy: patients, interventions, and outcomes--a report from a consensus meeting. 
  • Fraction of positive cores in prostate needle biopsy is significantly predictive of pathological stage in radical prostatectomy. 
  • Freedom from a detectable ultrasensitive prostate-specific antigen at two years after radical prostatectomy predicts a favorable clinical outcome: analysis of the SEARCH database. 
  • Gastrointestinal toxicity of transperineal interstitial prostate brachytherapy. 
  • Gene therapy for prostate cancer: where are we now? 
  • Gleason Grading, Biochemical Failure, and Prostate Cancer-Specific Death. 
  • Glucocorticoids manifest androgenic activity in a cell line derived from a metastatic prostate cancer. 
  • Guideline for the management of clinically localized prostate cancer: 2007 update. 
  • Hierarchical Bayesian mixture modelling for antigen-specific T-cell subtyping in combinatorially encoded flow cytometry studies. 
  • High-intensity focused ultrasound for prostate cancer: comparative definitions of biochemical failure. 
  • Higher doses of mitoxantrone among men with hormone-refractory prostate carcinoma: a Cancer and Leukemia Group B study. 
  • Highlights in advanced prostate cancer from the 2014 AUA and ASCO meetings. 
  • Hormonal therapy options for biochemical recurrence of prostate cancer after local therapy. 
  • Hormonal therapy options for prostate-specific antigen-only recurrence of prostate cancer after previous local therapy. 
  • Hormone naïve prostate cancer: predicting and maximizing response intervals. 
  • Human dendritic cells transfected with RNA encoding prostate-specific antigen stimulate prostate-specific CTL responses in vitro. 
  • Hypertension, obesity and prostate cancer biochemical recurrence after radical prostatectomy. 
  • Identification of a positive regulatory element responsible for tissue-specific expression of prostate-specific antigen. 
  • Identifying appropriate patients for early salvage radiotherapy after prostatectomy. 
  • Image Guided Hypofractionated Postprostatectomy Intensity Modulated Radiation Therapy for Prostate Cancer. 
  • Immunohistologic detection of prostate cancer pelvic lymph node micrometastases: correlation to preoperative serum prostate-specific antigen. 
  • Immunologic and prognostic factors associated with overall survival employing a poxviral-based PSA vaccine in metastatic castrate-resistant prostate cancer. 
  • Immunoreactive prostatic specific antigen in male periurethral glands. 
  • Impact of nerve sparing on surgical margins and biochemical recurrence: results from the SEARCH database. 
  • Impact of obesity on biochemical control after radical prostatectomy for clinically localized prostate cancer: a report by the Shared Equal Access Regional Cancer Hospital database study group. 
  • Impact of obesity on the utility of preoperative prostate-specific antigen velocity to predict for relapse after prostatectomy: a report from the SEARCH database. 
  • Impact of postoperative prostate-specific antigen disease recurrence and the use of salvage therapy on the risk of death. 
  • Impact of primary Gleason grade on risk stratification for Gleason score 7 prostate cancers. 
  • Impact of radical prostatectomy in the management of clinically localized disease. 
  • Impact of socioeconomic status and race on clinical parameters of patients undergoing radical prostatectomy in an equal access health care system. 
  • Importance of prostate volume in the European Randomised Study of Screening for Prostate Cancer (ERSPC) risk calculators: results from the prostate biopsy collaborative group. 
  • Importance of serum hemoglobin in hormone refractory prostate cancer. 
  • Improved prostate cancer-specific survival and other disease parameters: impact of prostate-specific antigen testing. 
  • Improvements in pathologic staging for African-American men undergoing radical retropubic prostatectomy during the prostate specific antigen era: implications for screening a high-risk group for prostate carcinoma. 
  • In regard to Lee et al.: "Dosimetry and cancer control after low-dose-rate prostate brachytherapy" (Int J Radiat Oncol Biol Phys 2005;61:52-59). 
  • Increasing prostate-specific antigen profile following definitive radiation therapy for localized prostate cancer: clinical observations. 
  • Induction androgen deprivation plus prostatectomy for stage T3 disease: failure to achieve prostate-specific antigen-based freedom from disease status in a phase II trial. 
  • Induction of polyclonal prostate cancer-specific CTL using dendritic cells transfected with amplified tumor RNA. 
  • Inflammatory infiltrate (prostatitis) in whole mounted radical prostatectomy specimens from black and white patients is not an etiology for racial difference in prostate specific antigen. 
  • Information content of five nomograms for outcomes in prostate cancer. 
  • Informed consent. From bodily invasion to the seemingly mundane. 
  • Initial decline in hemoglobin during neoadjuvant hormonal therapy predicts for early prostate specific antigen failure following radiation and hormonal therapy for patients with intermediate and high-risk prostate cancer. 
  • Initial prostate specific antigen 1.5 ng/ml or greater in men 50 years old or younger predicts higher prostate cancer risk. 
  • Initiation of salvage therapy for prostate cancer. 
  • Insulin-like growth factor binding protein 2: an androgen-dependent predictor of prostate cancer survival. 
  • Intermediate end point for prostate cancer-specific mortality following salvage hormonal therapy for prostate-specific antigen failure. 
  • Inverse correlation between body mass index and clinical outcomes in men with advanced castration-recurrent prostate cancer. 
  • Investigation momentum: the relentless pursuit to resolve uncertainty. 
  • Invited commentary: Lower urinary tract symptoms and inflammation--weighing the evidence. 
  • Is PSA related to serum cholesterol and does the relationship differ between black and white men? 
  • Is a positive bladder neck margin truly a T4 lesion in the prostate specific antigen era? Results from the SEARCH Database. 
  • Is biopsy Gleason score independently associated with biochemical progression following radical prostatectomy after adjusting for pathological Gleason score? 
  • Is computed tomography a necessary part of a metastatic evaluation for castration-resistant prostate cancer? Results from the Shared Equal Access Regional Cancer Hospital Database. 
  • Is prostate specific antigen of clinical importance in evaluating outcome after radical prostatectomy. 
  • Is the PSA test useless? 
  • Ketoconazole retains activity in patients with docetaxel-refractory prostate cancer. 
  • Ligation of prostate cancer cell surface GRP78 activates a proproliferative and antiapoptotic feedback loop: a role for secreted prostate-specific antigen. 
  • Limitations of Prostate-specific Antigen Testing After a Prostate Cancer Diagnosis. 
  • Limitations of prostate specific antigen doubling time following biochemical recurrence after radical prostatectomy: results from the SEARCH database. 
  • Limitations of tissue microarrays in the evaluation of focal alterations of bcl-2 and p53 in whole mount derived prostate tissues. 
  • Limited value of bone scintigraphy and computed tomography in assessing biochemical failure after radical prostatectomy. 
  • Localized carcinoma of the prostate (stages T1B, T1C, T2, and T3). Review of management with external beam radiation therapy. 
  • Localized prostate cancer treated by external-beam radiotherapy alone: serum prostate-specific antigen--driven outcome analysis. 
  • Long-term oncological outcomes of men undergoing radical prostatectomy with preoperative prostate-specific antigen <2.5 ng/ml and 2.5-4 ng/ml. 
  • Long-term outcomes of radical prostatectomy with multimodal adjuvant therapy in men with a preoperative serum prostate-specific antigen level > or =50 ng/mL. 
  • Long-term results of a phase II trial of ultrasound-guided radioactive implantation of the prostate for definitive management of localized adenocarcinoma of the prostate (RTOG 98-05). 
  • Long-term results of an RTOG Phase II trial (00-19) of external-beam radiation therapy combined with permanent source brachytherapy for intermediate-risk clinically localized adenocarcinoma of the prostate. 
  • Long-term testosterone gel (AndroGel) treatment maintains beneficial effects on sexual function and mood, lean and fat mass, and bone mineral density in hypogonadal men. 
  • Long-term tolerability and efficacy of degarelix: 5-year results from a phase III extension trial with a 1-arm crossover from leuprolide to degarelix. 
  • Low-risk prostate cancer patient: active treatment. 
  • Management of Postprostatectomy Biochemical Relapse With Salvage Radiotherapy: Results of an International Survey. 
  • Management of biochemical recurrence after primary treatment of prostate cancer: a systematic review of the literature. 
  • Management of the patient with a rising PSA alone. 
  • Mandated coverage for cancer-screening services: whose guidelines do states follow? 
  • Massive locally extensive prostate cancer. 
  • Medical center characteristics associated with PSA screening in elderly veterans with limited life expectancy. 
  • Medical technologies for the diagnosis of prostate cancer. 
  • Men older than 70 years have higher risk prostate cancer and poorer survival in the early and late prostate specific antigen eras. 
  • Men's Eating and Living (MEAL) study (CALGB 70807 [Alliance]): recruitment feasibility and baseline demographics of a randomized trial of diet in men on active surveillance for prostate cancer. 
  • Metabolic syndrome-like components and prostate cancer risk: results from the Reduction by Dutasteride of Prostate Cancer Events (REDUCE) study. 
  • Metformin use and risk of prostate cancer: results from the REDUCE study. 
  • Molecular and immunological analysis of genetic prostate specific antigen (PSA) vaccine. 
  • Molecular implications of the antiandrogen withdrawal syndrome. 
  • Molecular markers in prostate cancer: the role in preoperative staging. 
  • Morbidity and prostate-specific antigen control of external beam radiation therapy plus low-dose-rate brachytherapy boost for low, intermediate, and high-risk prostate cancer. 
  • Most Gleason 8 Biopsies are Downgraded at Prostatectomy-Does 4 + 4 = 7? 
  • Most of patients with localized prostate cancer will be treated in the future? | Opinion: No. 
  • Multi-institutional validation of the CAPRA-S score to predict disease recurrence and mortality after radical prostatectomy. 
  • Multicenter clinical validation of PITX2 methylation as a prostate specific antigen recurrence predictor in patients with post-radical prostatectomy prostate cancer. 
  • Multicenter phase 2 study of neoadjuvant paclitaxel, estramustine phosphate, and carboplatin plus androgen deprivation before radiation therapy in patients with unfavorable-risk localized prostate cancer: results of Cancer and Leukemia Group B 99811. 
  • Multivariate models as predictors of pathological stage using Gleason score, clinical stage, and serum prostate-specific antigen. 
  • Multivariate statistical analysis for pathologist. Part I, The logistic model. 
  • NADiA ProsVue prostate-specific antigen slope is an independent prognostic marker for identifying men at reduced risk of clinical recurrence of prostate cancer after radical prostatectomy. 
  • NADiA ProsVue prostate-specific antigen slope, CAPRA-S, and prostate cancer--specific survival after radical prostatectomy. 
  • NCCN clinical practice guidelines in oncology: prostate cancer. 
  • Natural history of persistently elevated prostate specific antigen after radical prostatectomy: results from the SEARCH database. 
  • Neoadjuvant docetaxel before radical prostatectomy in patients with high-risk localized prostate cancer. 
  • Neoadjuvant doxil chemotherapy prior to androgen ablation plus radiotherapy for high-risk localized prostate cancer: feasibility and toxicity. 
  • Neutropenia as a potential pharmacodynamic marker for docetaxel-based chemotherapy in men with metastatic castration-resistant prostate cancer. 
  • Note on "simulation optimization of PSA-threshold based prostate cancer screening policies". 
  • Null association between vitamin D and PSA levels among black men in a vitamin D supplementation trial. 
  • Obese African-Americans with prostate cancer (T1c and a prostate-specific antigen, PSA, level of <10 ng/mL) have higher-risk pathological features and a greater risk of PSA recurrence than non-African-Americans. 
  • Obesity and oncological outcome after radical prostatectomy: impact of prostate-specific antigen-based prostate cancer screening: results from the Shared Equal Access Regional Cancer Hospital and Duke Prostate Center databases. 
  • Obesity and prostate cancer: making sense out of apparently conflicting data. 
  • Obesity and survival after radical prostatectomy: A 10-year prospective cohort study. 
  • Obesity as a predictor of adverse outcome across black and white race: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) Database. 
  • Obesity is a significant risk factor for prostate cancer at the time of biopsy. 
  • Obesity, prostate-specific antigen nadir, and biochemical recurrence after radical prostatectomy: biology or technique? Results from the SEARCH database. 
  • Obesity, serum prostate specific antigen and prostate size: implications for prostate cancer detection. 
  • Obesity-related plasma hemodilution and PSA concentration among men with prostate cancer. 
  • Observations of pretreatment prostate-specific antigen doubling time in 107 patients referred for definitive radiotherapy. 
  • On model specification and selection of the Cox proportional hazards model. 
  • Optimal timing, cutoff, and method of calculation of preoperative prostate-specific antigen velocity to predict relapse after prostatectomy: a report from SEARCH. 
  • Optimization of PSA screening policies: a comparison of the patient and societal perspectives. 
  • Optimization of conformal radiation treatment of prostate cancer: report of a dose escalation study. 
  • Optimizing treatment for men with advanced prostate cancer: expert recommendations and the multidisciplinary approach. 
  • Orchiectomy and nilutamide or placebo as treatment of metastatic prostatic cancer in a multinational double-blind randomized trial. 
  • Outcome for repeated biopsy of the prostate: roles of serum PSA, small atypical glands, and prostatic intraepithelial neoplasia. 
  • Outcomes after radical prostatectomy among men who are candidates for active surveillance: results from the SEARCH database. 
  • PSA in the new millennium: a powerful predictor of prostate cancer prognosis and radical prostatectomy outcomes--results from the SEARCH database. 
  • PSA progression following radical prostatectomy and radiation therapy: new standards in the new Millennium. 
  • PSA thresholds for prostate cancer detection. 
  • PSCA polymorphisms and gastric cancer susceptibility in an eastern Chinese population. 
  • Paclitaxel, estramustine phosphate, and carboplatin in patients with advanced prostate cancer. 
  • Pain, PSA flare, and bone scan response in a patient with metastatic castration-resistant prostate cancer treated with radium-223, a case report. 
  • Paraneoplastic limbic encephalitis associated with small cell carcinoma of the prostate. 
  • Pathologic stage T2a and T2b prostate cancer in the recent prostate-specific antigen era: implications for unilateral ablative therapy. 
  • Pathologic variables and recurrence rates as related to obesity and race in men with prostate cancer undergoing radical prostatectomy. 
  • Pathological T2 sub-divisions as a prognostic factor in the biochemical recurrence of prostate cancer. 
  • Pathological outcomes and biochemical progression in men with T1c prostate cancer undergoing radical prostatectomy with prostate specific antigen 2.6 to 4.0 vs 4.1 to 6.0 ng/ml. 
  • Patient-physician communication about early stage prostate cancer: analysis of overall visit structure. 
  • Patterns of care for elderly men diagnosed with favorable-risk prostate cancer from 2004 to 2008: a population-based analysis. 
  • Patterns-of-failure analysis of patients with high pretreatment prostate-specific antigen levels treated by radiation therapy: the need for improved systemic and locoregional treatment. 
  • Percent tumor involvement and risk of biochemical progression after radical prostatectomy. 
  • Percentage of tumor in prostatectomy specimens: a study of American Veterans. 
  • Personalized prediction of tumor response and cancer progression on prostate needle biopsy. 
  • Pharmacodynamic study of disulfiram in men with non-metastatic recurrent prostate cancer. 
  • Pharmacological uncoupling of androgen receptor-mediated prostate cancer cell proliferation and prostate-specific antigen secretion. 
  • Phase 1 trial of neoadjuvant radiation therapy before prostatectomy for high-risk prostate cancer. 
  • Phase 1/2 multiple ascending dose trial of the prostate-specific membrane antigen-targeted antibody drug conjugate MLN2704 in metastatic castration-resistant prostate cancer. 
  • Phase 2 Study of Weekly Paclitaxel Plus Estramustine in Metastatic Hormone-Refractory Prostate Carcinoma: ECOG-ACRIN Cancer Research Group (E1898) Trial. 
  • Phase 2 Study of the Safety and Antitumor Activity of Apalutamide (ARN-509), a Potent Androgen Receptor Antagonist, in the High-risk Nonmetastatic Castration-resistant Prostate Cancer Cohort. 
  • Phase I-II prospective dose-escalating trial of lycopene in patients with biochemical relapse of prostate cancer after definitive local therapy. 
  • Phase II evaluation of oral estramustine, oral etoposide, and intravenous paclitaxel in patients with hormone-sensitive prostate adenocarcinoma. 
  • Phase II study of cilengitide (EMD 121974, NSC 707544) in patients with non-metastatic castration resistant prostate cancer, NCI-6735. A study by the DOD/PCF prostate cancer clinical trials consortium. 
  • Phase II study of low-dose docetaxel/estramustine in elderly patients or patients aged 18-74 years with hormone-refractory prostate cancer. 
  • Phase II study of single-agent orteronel (TAK-700) in patients with nonmetastatic castration-resistant prostate cancer and rising prostate-specific antigen. 
  • Phase II trial of single-agent weekly docetaxel in hormone-refractory, symptomatic, metastatic carcinoma of the prostate. 
  • Phase II trial of sunitinib for the therapy of progressive metastatic castration-refractory prostate cancer after previous docetaxel chemotherapy. 
  • Phase III study of mitoxantrone plus low dose prednisone versus low dose prednisone alone in patients with asymptomatic hormone refractory prostate cancer. 
  • Phase III trial of selenium to prevent prostate cancer in men with high-grade prostatic intraepithelial neoplasia: SWOG S9917. 
  • Phase III, randomized, placebo-controlled study of docetaxel in combination with zibotentan in patients with metastatic castration-resistant prostate cancer. 
  • Pilot study of dietary fat restriction and flaxseed supplementation in men with prostate cancer before surgery: exploring the effects on hormonal levels, prostate-specific antigen, and histopathologic features. 
  • Pilot study to explore effects of low-fat, flaxseed-supplemented diet on proliferation of benign prostatic epithelium and prostate-specific antigen. 
  • Platinum sensitivity in metastatic prostate cancer: does histology matter? 
  • Polymorphisms in the prostate-specific antigen gene promoter do not predict serum prostate-specific antigen levels in African-American men. 
  • Population screening for prostate cancer and emerging concepts for young men. 
  • Positive surgical margins in radical prostatectomy patients do not predict long-term oncological outcomes: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) cohort. 
  • Post-radical prostatectomy management options for positive surgical margins: argument for observation. 
  • Postoperative Radiation Therapy for Prostate Cancer: Comparison of Conventional Versus Hypofractionated Radiation Regimens. 
  • Postoperative prostate-specific antigen as a prognostic indicator in patients with margin-positive prostate cancer, undergoing adjuvant radiotherapy after radical prostatectomy. 
  • Postoperative prostate-specific antigen nadir improves accuracy for predicting biochemical recurrence after radical prostatectomy: Results from the Shared Equal Access Regional Cancer Hospital (SEARCH) and Duke Prostate Center databases. 
  • Potential selection bias in a community-based study of PSA levels in African-American men. 
  • Practice patterns and predictors of followup imaging after a negative bone scan in men with castration resistant prostate cancer: results from the SEARCH database. 
  • Predicting and monitoring results of therapy. 
  • Predicting biochemical recurrence after radical prostatectomy for patients with organ-confined disease using p27 expression. 
  • Predicting biopsy-proven prostate cancer recurrence following cryosurgery. 
  • Predicting bone scan positivity after biochemical recurrence following radical prostatectomy in both hormone-naive men and patients receiving androgen-deprivation therapy: results from the SEARCH database. 
  • Predicting bone scan positivity in non-metastatic castration-resistant prostate cancer. 
  • Predicting non-organ-confined prostate cancer in men diagnosed after 2000. 
  • Predicting prostate biopsy results: The importance of PSA, age, and race. 
  • Predicting prostate cancer mortality among men with intermediate to high-risk disease and multiple unfavorable risk factors. 
  • Predicting risk of prostate specific antigen recurrence after radical prostatectomy with the Center for Prostate Disease Research and Cancer of the Prostate Strategic Urologic Research Endeavor databases. 
  • Predicting the pathology results of radical prostatectomy from preoperative information: a validation study. 
  • Predicting tumor failure in prostate carcinoma after definitive radiation therapy: limitations of models based on prostate-specific antigen, clinical stage, and Gleason score. 
  • Predicting unilateral prostate cancer based on biopsy features: implications for focal ablative therapy--results from the SEARCH database. 
  • Prediction of survival following first-line chemotherapy in men with castration-resistant metastatic prostate cancer. 
  • Predictive probability of serum prostate-specific antigen for prostate cancer: an approach using Bayes rule. 
  • Predictors of extracapsular extension and positive margins in African American and white men. 
  • Predictors of metastatic disease in men with biochemical failure following radical prostatectomy. 
  • Predictors of prostate cancer-specific mortality after radical prostatectomy or radiation therapy. 
  • Predictors of secondary treatment following biochemical recurrence after radical prostatectomy: results from the Shared Equal Access Regional Cancer Hospital database. 
  • Preoperative predictors of pathologic stage T2a and pathologic Gleason score ≤ 6 in men with clinical low-risk prostate cancer treated with radical prostatectomy: reference for active surveillance. 
  • Preoperative predictors of pathologic stage T2a in low-risk prostate cancer: implications for focal therapy. 
  • Pretreatment expectations of patients undergoing robotic assisted laparoscopic or open retropubic radical prostatectomy. 
  • Pretreatment prostate-specific antigen doubling times: clinical utility of this predictor of prostate cancer behavior. 
  • Pretreatment prostate-specific antigen velocity is associated with freedom from biochemical recurrence of prostate cancer after low-dose-rate prostate brachytherapy alone. 
  • Pretreatment total testosterone level predicts pathological stage in patients with localized prostate cancer treated with radical prostatectomy. 
  • Preventing pain during office biopsy of the prostate: a single center, prospective, double-blind, 3-arm, parallel group, randomized clinical trial. 
  • Primary Cryotherapy for High-Grade Clinically Localized Prostate Cancer: Oncologic and Functional Outcomes from the COLD Registry. 
  • Primary care providers' perspectives on discontinuing prostate cancer screening. 
  • Primary care providers' response to the US Preventive Services Task Force draft recommendations on screening for prostate cancer. 
  • Primary hormonal therapy for prostate cancer: experience with 135 consecutive PSA-ERA patients from a tertiary care military medical center. 
  • Probability of an abnormal screening prostate-specific antigen result based on age, race, and prostate-specific antigen threshold. 
  • Prognostic impact of the neutrophil-to-lymphocyte ratio in men with metastatic castration-resistant prostate cancer. 
  • Prognostic indicators for long term outcome following radical retropubic prostatectomy for prostate cancer involving the seminal vesicles. 
  • Prognostic indicators in hormone refractory prostate cancer. 
  • Prognostic model predicting metastatic castration-resistant prostate cancer survival in men treated with second-line chemotherapy. 
  • Prognostic significance of reverse transcriptase polymerase chain reaction for prostate-specific antigen in men with hormone-refractory prostate cancer. 
  • Prognostic significance of reverse transcriptase polymerase chain reaction for prostate-specific antigen in metastatic prostate cancer: a nested study within CALGB 9583. 
  • Prognostic utility of cell cycle progression score in men with prostate cancer after primary external beam radiation therapy. 
  • Prognostic value of PTEN loss in men with conservatively managed localised prostate cancer. 
  • Prognostic value of a cell cycle progression signature for prostate cancer death in a conservatively managed needle biopsy cohort. 
  • Prognostic value of various morphometric measurements of tumour extent in prostate needle core tissue. 
  • Progression-free survival as a predictor of overall survival in men with castrate-resistant prostate cancer. 
  • Propensity Score-Matched Comparison of Partial to Whole-Gland Cryotherapy for Intermediate-Risk Prostate Cancer: An Analysis of the Cryo On-Line Data Registry Data. 
  • Prospective use of free PSA to avoid repeat prostate biopsies in men with elevated total PSA. 
  • Prostate Cancer Disseminated Tumor Cells are Rarely Detected in the Bone Marrow of Patients with Localized Disease Undergoing Radical Prostatectomy across Multiple Rare Cell Detection Platforms. 
  • Prostate Specific Antigen Density as a Predictor of Clinically Significant Prostate Cancer When the Prostate Specific Antigen is in the Diagnostic Gray Zone: Defining the Optimum Cutoff Point Stratified by Race and Body Mass Index. 
  • Prostate Specific Antigen Nadir of 0.1 or Less Is a Predictor of Treatment Success in Men Undergoing Salvage Whole Prostate Gland Cryoablation. 
  • Prostate Specific Antigen Working Group guidelines on prostate specific antigen doubling time. 
  • Prostate biopsies from black men express higher levels of aggressive disease biomarkers than prostate biopsies from white men. 
  • Prostate biopsy quantitative histology as a staging and prognostic factor. 
  • Prostate brachytherapy: a descriptive analysis from CaPSURE. 
  • Prostate cancer 1997--practicing what we preach. 
  • Prostate cancer as a public health issue in North Carolina. 
  • Prostate cancer cell proliferation in vitro is modulated by antibodies against glucose-regulated protein 78 isolated from patient serum. 
  • Prostate cancer early detection practices among men with a family history of disease. 
  • Prostate cancer in men age 50 years or younger: a review of the Department of Defense Center for Prostate Disease Research multicenter prostate cancer database. 
  • Prostate cancer in the Baby Boomer generation: results from CaPSURE. 
  • Prostate cancer in young men: an important clinical entity. 
  • Prostate cancer laterality does not predict prostate-specific antigen recurrence after radical prostatectomy. 
  • Prostate cancer mortality after introduction of prostate-specific antigen mass screening in the Federal State of Tyrol, Austria. 
  • Prostate cancer risk in men with baseline history of coronary artery disease: results from the REDUCE Study. 
  • Prostate cancer screening. 
  • Prostate cancer screening. Why the controversy? 
  • Prostate cancer with solitary parotid metastasis correctly diagnosed with immunohistochemical stains. 
  • Prostate cancer-specific mortality after radical prostatectomy or external beam radiation therapy in men with 1 or more high-risk factors. 
  • Prostate cancer-specific survival following salvage radiotherapy vs observation in men with biochemical recurrence after radical prostatectomy. 
  • Prostate cancer. 
  • Prostate cancer. 
  • Prostate cancer: an evolving paradigm. 
  • Prostate cancer: the new landscape. 
  • Prostate epithelial cell of origin determines cancer differentiation state in an organoid transformation assay. 
  • Prostate size and risk of high-grade, advanced prostate cancer and biochemical progression after radical prostatectomy: a search database study. 
  • Prostate specific antigen density is not an independent predictor of response for prostate cancer treated by conformal radiotherapy. 
  • Prostate specific antigen doubling time as a surrogate end point for prostate cancer specific mortality following radical prostatectomy or radiation therapy. 
  • Prostate specific antigen kinetics at tumor recurrence after radical prostatectomy do not suggest a worse disease prognosis in black men. 
  • Prostate specific antigen nadir following external beam radiation therapy for clinically localized prostate cancer: the relationship between nadir level and disease-free survival. 
  • Prostate specific antigen only progression of prostate cancer. 
  • Prostate specific antigen recurrence after definitive therapy. 
  • Prostate specific antigen testing in men older than 75 years in the United States. 
  • Prostate specific antigen: a decade of discovery--what we have learned and where we are going. 
  • Prostate-Specific Membrane Antigen-Targeted Radiohalogenated PET and Therapeutic Agents for Prostate Cancer. 
  • Prostate-specific antigen (PSA) and PSA velocity for prostate cancer detection in men aged <50 years. 
  • Prostate-specific antigen 1.5-4.0 ng/mL: a diagnostic challenge and danger zone. 
  • Prostate-specific antigen and pain surrogacy analysis in metastatic hormone-refractory prostate cancer. 
  • Prostate-specific antigen as a marker of disease activity in prostate cancer. 
  • Prostate-specific antigen as a marker of disease activity in prostate cancer. 
  • Prostate-specific antigen changes as surrogate for overall survival in men with metastatic castration-resistant prostate cancer treated with second-line chemotherapy. 
  • Prostate-specific antigen endpoints in hormone-refractory prostate cancer. 
  • Prostate-specific antigen in black men. 
  • Prostate-specific antigen level, stage or Gleason score: which is best for predicting outcomes after radical prostatectomy, and does it vary by the outcome being measured? Results from Shared Equal Access Regional Cancer Hospital database. 
  • Prostate-specific antigen levels in young white and black men 20 to 45 years old. 
  • Prostate-specific antigen nadir and cancer-specific mortality following hormonal therapy for prostate-specific antigen failure. 
  • Prostate-specific antigen response in black and white patients treated with abiraterone acetate for metastatic castrate-resistant prostate cancer. 
  • Prostate-specific antigen screening among young men in the United States. 
  • Prostate-specific antigen to predict outcome of external beam radiation for prostate cancer: Walter Reed Army Medical Center experience, 1988-1995. 
  • Prostate-specific antigen values at the time of prostate cancer diagnosis in African-American men. 
  • Prostate-specific antigen velocity based risk-adapted discontinuation of prostate cancer screening in elderly men. 
  • Prostate-specific antigen velocity: new methods, same results, still no evidence of clinical utility. 
  • Prostate-specific antigen versus prostate-specific antigen density as predictor of tumor volume, margin status, pathologic stage, and biochemical recurrence of prostate cancer. 
  • Prostate-specific antigen-based risk-adapted discontinuation of prostate cancer screening in elderly African American and Caucasian American men. 
  • Prostate-specific antigen-based serial screening may decrease prostate cancer-specific mortality. 
  • Prostate-specific antigen-detected prostate cancer (stage T1c): an analysis of whole-mount prostatectomy specimens. 
  • Prostate-specific antigen-enhanced testing and risk stratification for chemoprevention trials. 
  • Prostatic carcinosarcoma 15 years after combined external beam radiation and brachytherapy for prostatic adenocarcinoma: a case report. 
  • Psychosocial trajectories of men monitoring prostate-specific antigen levels following surgery for prostate cancer. 
  • Public survey and survival data do not support recommendations to discontinue prostate-specific antigen screening in men at age 75. 
  • Quality of life associated with treatment of castration-resistant prostate cancer: a review of the literature. 
  • Quantitative expression profile of PSGR in prostate cancer. 
  • Race and prostate weight as independent predictors for biochemical recurrence after radical prostatectomy. 
  • Race and the linkage between serum prostate-specific antigen and prostate cancer: a study of American veterans. 
  • Race, biochemical disease recurrence, and prostate-specific antigen doubling time after radical prostatectomy: results from the SEARCH database. 
  • Race/ethnicity and the intensity of medical monitoring under 'watchful waiting' for prostate cancer. 
  • Racial differences in prostate cancer screening by family history. 
  • Racial differences in tumor volume and prostate specific antigen among radical prostatectomy patients. 
  • Radical perineal prostatectomy: a model for evaluating local response of prostate therapy. 
  • Radical perineal prostatectomy: oncological outcome during a 20-year period. 
  • Radical prostatectomy for clinical stage T3a disease. 
  • Radical prostatectomy lowers plasma vascular endothelial growth factor levels in patients with prostate cancer. 
  • Radical prostatectomy versus radiation therapy: can pretreatment nomograms be used to select the appropriate prostate cancer treatment? 
  • Radical radiation therapy in the management of prostatic adenocarcinoma: the initial prostate specific antigen value as a predictor of treatment outcome. 
  • Radiographic progression with nonrising PSA in metastatic castration-resistant prostate cancer: post hoc analysis of PREVAIL. 
  • Radiotherapy for locally recurrent prostate cancer. 
  • Randomized study of three different doses of suramin administered with a fixed dosing schedule in patients with advanced prostate cancer: results of intergroup 0159, cancer and leukemia group B 9480. 
  • Randomized, double-blind, placebo-controlled phase III trial comparing docetaxel and prednisone with or without bevacizumab in men with metastatic castration-resistant prostate cancer: CALGB 90401. 
  • Rapid rise of serum prostate specific antigen levels after discontinuation of the herbal therapy PC-SPES in patients with advanced prostate carcinoma: report of four cases. 
  • Re: Prostate-specific antigen: a misused and maligned prostate cancer biomarker. 
  • Re: the economic burden of metastatic and prostate specific antigen progression in patients with prostate cancer: findings from a retrospective analysis of health plan data. 
  • Real-time quantitative RT-PCR assay of prostate-specific antigen and prostate-specific membrane antigen in peripheral blood for detection of prostate cancer micrometastasis. 
  • Reassessing the diagnostic yield of saturation biopsy of the prostate. 
  • Reduced Core Targeted (RCT) biopsy: Combining multiparametric magnetic resonance imaging - transrectal ultrasound fusion targeted biopsy with laterally-directed sextant biopsies - An alternative template for prostate fusion biopsy. 
  • Reduction of human prostate tumor vascularity by the alpha1-adrenoceptor antagonist terazosin. 
  • Reference ranges for serum prostate-specific antigen in black and white men without cancer. 
  • Reply: To PMID 25432832. 
  • Report from Durham. 
  • Residual disease after radical surgery or radiation therapy for prostate cancer. Clinical significance and therapeutic implications. 
  • Response to docetaxel/carboplatin in patients with hormone-refractory prostate cancer not responding to taxane-based chemotherapy. 
  • Results of a phase II trial of transrectal ultrasound-guided permanent radioactive implantation of the prostate for definitive management of localized adenocarcinoma of the prostate (radiation therapy oncology group 98-05). 
  • Results of radical prostatectomy in men with locally advanced prostate cancer: multi-institutional pooled analysis. 
  • Reversal of PSA progression on abiraterone acetate through the administration with food in men with metastatic castration-resistant prostate cancer. 
  • Rising PSA Level in an Anxious Postprostatectomy Patient. 
  • Rising PSA after local therapy failure: immediate vs deferred treatment. 
  • Rising PSA in nonmetastatic prostate cancer. 
  • Rising prostate-specific antigen after primary prostate cancer therapy. 
  • Risk Stratification Among Men With Prostate Imaging Reporting and Data System version 2 Category 3 Transition Zone Lesions: Is Biopsy Always Necessary? 
  • Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. 
  • Rosiglitazone versus placebo for men with prostate carcinoma and a rising serum prostate-specific antigen level after radical prostatectomy and/or radiation therapy. 
  • Salvage Radiation Therapy Dose Response for Biochemical Failure of Prostate Cancer After Prostatectomy-A Multi-Institutional Observational Study. 
  • Salvage radiation in men after prostate-specific antigen failure and the risk of death. 
  • Salvage radiotherapy for rising or persistent PSA after radical prostatectomy. 
  • Sample size calculations for evaluating a diagnostic test when the gold standard is missing at random. 
  • Scatter factor-hepatocyte growth factor elevation in the serum of patients with prostate cancer. 
  • Screening for prostate cancer in African Americans. 
  • Screening for prostate cancer in high risk populations. 
  • Screening for prostate cancer utilizing the prostate-specific antigen (PSA). 
  • Screening, risk assessment, and the approach to therapy in patients with prostate cancer. 
  • Selective aromatase inhibition for patients with androgen-independent prostate carcinoma. 
  • Selenomethionine does not affect PSA secretion independent of its effect on LNCaP cell growth. 
  • Self-Assembling Peptide Gels for 3D Prostate Cancer Spheroid Culture. 
  • Semiparametric Bayesian modeling of random genetic effects in family-based association studies. 
  • Sequence of hormonal therapy and radiotherapy field size in unfavourable, localised prostate cancer (NRG/RTOG 9413): long-term results of a randomised, phase 3 trial. 
  • Serum Prostate-Specific Antigen (PSA) Concentration, PSA Mass, and Obesity: A Mathematical Analysis. 
  • Serum alkaline phosphatase changes predict survival independent of PSA changes in men with castration-resistant prostate cancer and bone metastasis receiving chemotherapy. 
  • Serum androgens: associations with prostate cancer risk and hair patterning. 
  • Serum lipid profile and risk of prostate cancer recurrence: Results from the SEARCH database. 
  • Serum prostate-specific antigen (PSA) concentration is positively associated with rate of disease reclassification on subsequent active surveillance prostate biopsy in men with low PSA density. 
  • Serum testosterone and dihydrotestosterone and prostate cancer risk in the placebo arm of the Reduction by Dutasteride of Prostate Cancer Events trial. 
  • Short-term cancer control after primary cryosurgical ablation for clinically localized prostate cancer using third-generation cryotechnology. 
  • Significance of tertiary Gleason pattern 5 in Gleason score 7 radical prostatectomy specimens. 
  • Significant discrepancies between diagnostic and pathologic Gleason sums in prostate cancer: the predictive role of age and prostate-specific antigen. 
  • Simulation optimization of PSA-threshold based prostate cancer screening policies. 
  • Smoking is a predictor of adverse pathological features at radical prostatectomy: Results from the Shared Equal Access Regional Cancer Hospital database. 
  • Stage T3 prostate cancer: a nonrandomized comparison between definitive irradiation and induction hormonal manipulation plus prostatectomy. 
  • Standardization of definitions in focal therapy of prostate cancer: report from a Delphi consensus project. 
  • Statin drugs, serum cholesterol, and prostate-specific antigen in the National Health and Nutrition Examination Survey 2001-2004. 
  • Statin medication use and the risk of biochemical recurrence after radical prostatectomy: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) Database. 
  • Statin medications are associated with a lower probability of having an abnormal screening prostate-specific antigen result. 
  • Statin use and risk of prostate cancer and high-grade prostate cancer: results from the REDUCE study. 
  • Statin use is associated with decreased prostate cancer recurrence in men treated with brachytherapy. 
  • Statistical modeling using preoperative prognostic variables in predicting extracapsular extension and progression after radical prostatectomy for prostate cancer. 
  • Stratification of pathologic features in radical prostatectomy specimens that are predictive of elevated initial postoperative serum prostate-specific antigen levels. 
  • Sunitinib in combination with docetaxel and prednisone in chemotherapy-naive patients with metastatic, castration-resistant prostate cancer: a phase 1/2 clinical trial. 
  • Surrogate end point for prostate cancer specific mortality in patients with nonmetastatic hormone refractory prostate cancer. 
  • Surrogate end point for prostate cancer-specific mortality after radical prostatectomy or radiation therapy. 
  • Surveillance after prostate focal therapy. 
  • Synergistic and tunable human gene activation by combinations of synthetic transcription factors. 
  • Systematic biopsies: do they add prognostic information in men with clinically localized prostate cancer treated with radiation therapy alone? 
  • Systemic therapy for prostate cancer. 
  • TET2 binds the androgen receptor and loss is associated with prostate cancer. 
  • TMPRSS2-ERG fusion, a common genomic alteration in prostate cancer activates C-MYC and abrogates prostate epithelial differentiation. 
  • Temporarily deferred therapy (watchful waiting) for men younger than 70 years and with low-risk localized prostate cancer in the prostate-specific antigen era. 
  • The COMPARE Registry: design and baseline patterns of care for men with biochemical failure after definitive treatment of localized prostate cancer. 
  • The Development of Intermediate Clinical Endpoints in Cancer of the Prostate (ICECaP). 
  • The Prostate cancer Intervention Versus Observation Trial:VA/NCI/AHRQ Cooperative Studies Program #407 (PIVOT): design and baseline results of a randomized controlled trial comparing radical prostatectomy to watchful waiting for men with clinically localized prostate cancer. 
  • The association between prostate size and Gleason score upgrading depends on the number of biopsy cores obtained: results from the Shared Equal Access Regional Cancer Hospital Database. 
  • The association between radiographic response and overall survival in men with metastatic castration-resistant prostate cancer receiving chemotherapy. 
  • The correlation of serial prostate specific antigen measurements with clinical outcome after external beam radiation therapy of patients for prostate carcinoma. 
  • The development of risk groups in men with metastatic castration-resistant prostate cancer based on risk factors for PSA decline and survival. 
  • The dynamics of death in prostate cancer. 
  • The dynamics of prostate specific antigen during watchful waiting of prostate carcinoma: a study of 94 Japanese men. 
  • The dynamics of prostate specific antigen in hormone refractory prostate carcinoma: an analysis of cancer and leukemia group B study 9181 of megestrol acetate. 
  • The dynamics of prostate-specific antigen after definitive radiation therapy for prostate cancer. 
  • The economic burden of metastatic and prostate specific antigen progression in patients with prostate cancer: findings from a retrospective analysis of health plan data. 
  • The effect of dutasteride on the usefulness of prostate specific antigen for the diagnosis of high grade and clinically relevant prostate cancer in men with a previous negative biopsy: results from the REDUCE study. 
  • The effect of noise-cancelling headphones or music on pain perception and anxiety in men undergoing transrectal prostate biopsy. 
  • The effect of pelvic radiation therapy on serum levels of prostate specific antigen. 
  • The effect of race on the discriminatory accuracy of models to predict biochemical recurrence after radical prostatectomy: results from the Shared Equal Access Regional Cancer Hospital and Duke Prostate Center databases. 
  • The effect of race/ethnicity on the accuracy of the 2001 Partin Tables for predicting pathologic stage of localized prostate cancer. 
  • The efficacy of postprostatectomy radiotherapy in patients with an isolated elevation of serum prostate-specific antigen. 
  • The evolving role of chemotherapy in androgen-independent (hormone-refractory) prostate cancer. 
  • The experiences of unpartnered men with prostate cancer: a qualitative analysis. 
  • The impact of PSA on prostate cancer management. Can we abandon routine staging pelvic lymphadenectomy? 
  • The influence of ejaculation on serum levels of prostate specific antigen. 
  • The influence of statin medications on prostate-specific antigen levels. 
  • The interplay between obesity and the accuracy of prostate-specific antigen (PSA) for predicting prostate cancer. 
  • The monomeric receptor binding domain of tetrameric α2-macroglobulin binds to cell surface GRP78 triggering equivalent activation of signaling cascades. 
  • The number of high-risk factors and the risk of prostate cancer-specific mortality after brachytherapy: implications for treatment selection. 
  • The percentage of prostate needle biopsy cores with carcinoma from the more involved side of the biopsy as a predictor of prostate specific antigen recurrence after radical prostatectomy: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database. 
  • The prognostic significance of plasma interleukin-6 levels in patients with metastatic hormone-refractory prostate cancer: results from cancer and leukemia group B 9480. 
  • The relationship between prostate-specific antigen and prostate cancer risk: the Prostate Biopsy Collaborative Group. 
  • The relative importance of anatomic and PSA factors to outcomes after radical prostatectomy for prostate cancer. 
  • The role of androgen deprivation therapy combined with prostate brachytherapy. 
  • The role of genetic markers in the management of prostate cancer. 
  • The role of radical prostatectomy in patients with pretreatment prostate-specific antigen > or = 40 ng/mL. 
  • The value of a baseline bone scan in patients with newly diagnosed prostate cancer. 
  • Time trends in biochemical recurrence after radical prostatectomy: results of the SEARCH database. 
  • Timing of androgen deprivation therapy and its impact on survival after radical prostatectomy: a matched cohort study. 
  • Treating the biochemical recurrence of prostate cancer after definitive primary therapy. 
  • Treatment of PSA only recurrence of prostate cancer after prior local therapy. 
  • Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3. 
  • Tumor length in prostate cancer. 
  • Tumor percent involvement predicts prostate specific antigen recurrence after radical prostatectomy only in men with smaller prostate. 
  • Tumor volume changes on 1.5 tesla endorectal MRI during neoadjuvant androgen suppression therapy for higher-risk prostate cancer and recurrence in men treated using radiation therapy results of the phase II CALGB 9682 study. 
  • Tumor volume in prostate cancer and serum prostate-specific antigen. Analysis from a kinetic viewpoint. 
  • Tumor volume, tumor percentage involvement, or prostate volume: which is predictive of prostate-specific antigen recurrence? 
  • Twenty-five year evolution of medical hormonal therapy for prostate cancer. 
  • Update on outcomes research databases in prostate cancer 2006. 
  • Updated prognostic model for predicting overall survival in first-line chemotherapy for patients with metastatic castration-resistant prostate cancer. 
  • Upgrading and downgrading of prostate needle biopsy specimens: risk factors and clinical implications. 
  • Use of local (111)in-capromab pendetide scan results to predict outcome after salvage radiotherapy for prostate cancer. 
  • Use of prostate-specific antigen in black men: age-adjusted reference ranges for maximal cancer detection. 
  • Use of prostate-specific antigen in the follow-up of patients with localized prostate cancer: results of a nationwide survey of urologists. 
  • Use of serum creatinine to predict pathologic stage and recurrence among radical prostatectomy patients. 
  • Using surrogate biomarkers to predict clinical benefit in men with castration-resistant prostate cancer: an update and review of the literature. 
  • Using the percentage of biopsy cores positive for cancer, pretreatment PSA, and highest biopsy Gleason sum to predict pathologic stage after radical prostatectomy: the Center for Prostate Disease Research nomograms. 
  • Validation of a cell-cycle progression gene panel to improve risk stratification in a contemporary prostatectomy cohort. 
  • Validation of a nomogram to predict disease progression following salvage radiotherapy after radical prostatectomy: results from the SEARCH database. 
  • Variables in predicting survival based on treating "PSA-only" relapse. 
  • Variation in the definition of biochemical recurrence in patients treated for localized prostate cancer: the American Urological Association Prostate Guidelines for Localized Prostate Cancer Update Panel report and recommendations for a standard in the reporting of surgical outcomes. 
  • Weekly docetaxel in elderly patients with prostate cancer: efficacy and toxicity in patients at least 70 years of age compared with patients younger than 70 years. 
  • Weight gain is associated with an increased risk of prostate cancer recurrence after prostatectomy in the PSA era. 
  • What are the factors associated with short prostate specific antigen doubling time after radical prostatectomy? A report from the SEARCH database group. 
  • What the U.S. Preventive Services Task Force missed in its prostate cancer screening recommendation. 
  • Young patients with prostate cancer have an outcome justifying their treatment with external beam radiation. 
  • p53 and bcl-2 immunohistochemistry in pretreatment prostate needle biopsies to predict recurrence of prostate cancer after radical prostatectomy. 
• 

  Keywords of People

  • Koontz, Bridget Fey, Associate Professor of Radiation Oncology, Radiation Oncology
  • McDonnell, Donald Patrick, Chair, Department of Pharmacology & Cancer Biology, Duke Innovation & Entrepreneurship
  • Moorman, Patricia Gripka, Professor in Family Medicine and Community Health, Duke Cancer Institute
  • Routh, Jonathan Charles, Paul H. Sherman, M.D. Associate Professor of Surgery, Pediatrics